The Pharmaceutical Sector Inquiry Preliminary Report: patent-related issues raised relevant to all patent intensive industries

Wragge & Co's first analysis of the EU Commission's preliminary report on the pharmaceutical sector looked at regulatory issues covered by the preliminary report. The IP team now moves on to consider the patent-related practices the preliminary report focused on.

Many of the practices that concern the EU Commission are common to other patent intensive industries. Therefore, whether or not the EU Commission's concerns relating to the pharmaceutical sector are justified, the relevance and possible implications of this preliminary report may stretch well beyond it.

Read Wragge & Co's expert analysis.